ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On January9, 2017, Ardelyx, Inc. (the Company) announced that as
of December31, 2016, the Company had approximately $201million in
cash and cash equivalents.
The information furnished under this Item 2.02 shall not be
considered filed under the Securities Exchange Act of 1934, as
amended (the Exchange Act), nor shall it be incorporated by
reference into any future filing under the Securities Act of
1933, as amended, or under the Exchange Act unless the Company
expressly sets forth in such future filing that such information
is to be considered filed or incorporated by reference therein.
Item7.01 |
Regulation FD Disclosure. |
Attached hereto as Exhibit 99.1 is a corporate presentation of
the Company incorporated by reference herein.
The information furnished under this Item 7.01 shall not be
considered filed under the Exchange Act, nor shall it be
incorporated by reference into any future filing under the
Securities Act of 1933, as amended, or under the Exchange Act
unless the Company expressly sets forth in such future filing
that such information is to be considered filed or incorporated
by reference therein.
Item9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
|
| 99.1 | Corporate presentation of Ardelyx, Inc. |
About ARDELYX, INC. (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program. ARDELYX, INC. (NASDAQ:ARDX) Recent Trading Information
ARDELYX, INC. (NASDAQ:ARDX) closed its last trading session up +0.90 at 13.85 with 352,310 shares trading hands.
